A U.S. drug company did not openly share or perform further studies on a successful rheumatoid arthritis medicine that internal researchers suggested was reducing the risk of Alzheimer's disease by 64 percent, according to Washington Post article published Tuesday. Researchers at Pfizer reportedly urged the firm to conduct a clinical trial after finding the potential hidden benefit of the anti-inflammatory drug Enbrel while analyzing insurance claims. It was estimated to cost $80 million to conduct the trial, and Pfizer decided to pass. Pfizer told the Post it did not pursue the clinical trial because its success rate would likely be...